You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Online Encyclopedia of Behavioral Medicine

    SBC: TALARIA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Treatment and prevention of many chronic health problems, such as HIV infection, are significantly influenced by stress and behavior. Yet, many healthcare providers and students lack knowledge about how stress and behavior interact with physiological processes such as immune and endocrine functions. The purpose of the present project is to produce an evidence-b ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  2. Venous Window Access Catheter For Hemodialysis

    SBC: VITAL ACCESS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): A novel, venous window access device (VWAD), anastomotic tool, and minimally invasive, image-guided surgical procedure to provide hemodialysis for patients suffering from End Stage Renal Disease (ESRD) have undergone early stage development. The device can serve as a destination therapy or as a bridge device to provide temporary access during maturation of an ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  3. Highly Parallel AIDS Assays Using A Microfluidic Flow Cell Array Integrated with

    SBC: Carterra, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The ultimate goal of this project is to develop a multiplex label free platform for high-throughput HIV specific serum antibody detection of patient samples. To help Wasatch Microfludics reach this ultimate goal, this proposal will address the feasibility of performing high throughput label free detection of serum antibodies to a variety of HIV proteins through ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Novel Her2/neu Expressing Adenovirus for Treatment

    SBC: Etubics Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): The objective of this project is to continue developing an adenoviral serotype 5 (Ad5) vector vaccine against Ad5[E1-, E2b]-Her2/neu that is effective in stimulating cell-mediated immunity (CMI) in animals previously immune to Ad5. The Ad5[E1-, E2b-]- Her2/neu vaccine endpoint is to treat patients with HER2 over expressing cancers. HER2 is a protein that has b ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  5. Development of an Ad5 [E1-, E2b-] HIV-1 vaccine for use in Ad5 Immunized Vaccinee

    SBC: Etubics Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Current generation Adenovirus (Ad) vector vaccines deleted at the E1 or the E1, E3 regions have resulted in experimental potential to immunize against a variety of infectious diseases such as HIV. These Ad vectors permit the delivery of genes, which express proteins that stimulate the immune system. An advanced generation of Ad vectors with unique deletions of ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Novel CEA Expressing Ad5 [E1-, E2b-] Vector for Treatment

    SBC: Etubics Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): The objective of this project is to continue to develop an adenoviral vector vaccine against CEA that is effective in stimulating cell-mediated immune responses in subjects previously immune to Adenovirus. The Ad-CEA vaccine endpoint is to treat patients with CEA bearing cancers. CEA is a tumor associated protein that has been reported to be useful as a vaccin ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  7. #255 DEVELOPMENT OF ANTICANCER AGENTS

    SBC: Etubics Corporation            Topic: N/A

    Location 410 W HARRISON ST, STE 100 SEATTLE, WA 98119 United States N43CO200900059 $149 976.00 2 009 #255 DEVELOPMENT OF ANTICANCER AGENTS Department of Health and Human Services National Institutes of Health SBIR PHS2009-1 Etubics Corporation Phase I N43 ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  8. Non-Invasive Drug Delivery to Treat Severe Uveitis

    SBC: ACIONT, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The overarching aim of this innovative proposal is to develop and then commercialize a non-invasive topical product which is safe and easy to administer that treats severe uveitis, including intermediate and posterior uveitis. Uveitis is the third leading cause of blindness in the United States. Heretofore, the primary treatments of intermediate and posterior u ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  9. EGF/Gastrin for islet cell regeneration

    SBC: PHARMAIN CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): New therapies are desperately needed to relieve patients with Type 1 diabetes from the neuropathy, nephropathy and retinopathy associated with the current standard of treatment, injected insulin. Transplantation of pancreatic islet cells in combination with immunosuppressant to avoid immune rejection is restricted to a subgroup of diabetics and is limited by th ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  10. Long-acting VIP formulations for the treatment of chronic inflammatory diseases

    SBC: PHARMAIN CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Despite the success of TNF-inhibitors and other new biological drugs for the treatment of autoimmune and other chronic inflammatory diseases, there are still many patients that are only poorly controlled. Vasoactive intestinal peptide (VIP) is an immunomodulatory peptide that induces regulatory T-cells and anti-inflammatory cytokine responses and has shown effi ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government